Trials Sponsors Conditions Drugs Pricing

Conditions

Hepatoid Adenocarcinoma of Stomach

Keywords

HER2SOXPD-1 inhibitorperioperative treatment

Outcome Measures

Primary Outcomes (1)

pathological complete response rate
The proportion of subjects with node-negative lymph nodes and without residual viable tumor cells in the total number of subjects
within 10 days after surgery

Secondary Outcomes (5)

major pathological response rate
Within 10 days after surgery
Objective response rate
From enrollment to surgery, assessed up to 3 months
Event-free survival
From date of enrollment until the date of first documented progression, recurrence or date of death from any cause, whichever came first, assessed up to 3 years
Disease free survival
From date of surgery until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 3 years
overall survival
From date of diagnosis until the date of death from any cause, assessed up to 3 years

Study Arms (1)

Perioperative treatment for hepatoid adenocarcinoma of stomach

EXPERIMENTAL

Drug: Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab.

Interventions

Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab.Drug

1. Neoadjuvant therapy for 4 cycles: albumin-bound paclitaxel 150mg/m2, intravenously, d1, a course of treatment every 21 days; sintilimab 200mg, intravenously, d1, every 21 days; tegafur,gimeracil and oteracil porassium (by body surface area: BSA\<1.25m2, 40mg; BSA≥1.25m2, \<1.5m2, 50mg; BSA≥1.5m2,60mg), orally, twice a day, d1-14, every 21 days; oxaliplatin 85mg/m2, intravenously, d1, every 21 days. 2. Radical surgical treatment should be performed within 4-6 weeks after the end of neoadjuvant therapy. 3. Adjuvant therapy for 4 cycles: albumin-bound paclitaxel 125mg/m2, intravenously, d1, a course of treatment every 21 days; sintilimab 200mg, intravenously, d1, every 21 days; tegafur,gimeracil and oteracil porassium (by body surface area: BSA\<1.25m2, 40mg; BSA≥1.25m2, \<1.5m2, 50mg; BSA≥1.5m2,60mg), orally, twice a day, d1-14, every 21 days.

Perioperative treatment for hepatoid adenocarcinoma of stomach

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Treatment programme
Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab.
The registry describes a treatment programme. Individual components, doses and actual administration are not established by this entry.
View registry record

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

The histological type of gastric hepatoid adenocarcinoma was confirmed by pathological biopsy；
HER2 negative (Immunohistochemistry: 0);

Sponsors & Collaborators

Peking University Cancer Hospital & Institute
Otherlead

Study Sites (1)

Peking University Cancer Hospital & Institute

Beijing, China

RECRUITING

Jialin Li, MDCONTACT861088196970 ljldoc@163.com

MeSH Terms

Interventions

Albumin-Bound PaclitaxelOxaliplatinTegafurgimeracilsintilimab

Intervention Hierarchy (Ancestors)

PaclitaxelTaxoidsCyclodecanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsDiterpenesTerpenes

Study Officials

Jiafu Ji, MD
Peking University Cancer Hospital & Institute
PRINCIPAL INVESTIGATOR

Central Study Contacts

Anqiang Wang, MD

CONTACT

861088196970 wanganqiang0902@163.com

Jialin Li, MD

CONTACT

861088196970

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Masking Details: Masking Description
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 10, 2025

First Posted

September 17, 2025

Study Start

September 18, 2025

Actual (reported)

Primary Completion

Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (1)

Perioperative treatment for hepatoid adenocarcinoma of stomach

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (1)

Perioperative treatment for hepatoid adenocarcinoma of stomach

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations